Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Liabilities and Shareholders Equity (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Liabilities and Shareholders Equity for 4 consecutive years, with $507.8 million as the latest value for Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 12.86% year-over-year to $507.8 million; the TTM value through Dec 2025 reached $2.1 billion, up 8.6%, while the annual FY2025 figure was $507.8 million, 12.86% down from the prior year.
  • Liabilities and Shareholders Equity was $507.8 million for Q4 2025 at Day One Biopharmaceuticals, down from $513.8 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $600.8 million in Q3 2024, with the low at $267.8 million in Q1 2022.
  • Historically, Liabilities and Shareholders Equity has averaged $434.6 million across 4 years, with a median of $409.1 million in 2022.
  • Biggest YoY gain for Liabilities and Shareholders Equity was 63.59% in 2025; the steepest drop was 14.49% in 2025.
  • Over 4 years, Liabilities and Shareholders Equity stood at $349.1 million in 2022, then increased by 7.73% to $376.0 million in 2023, then surged by 54.98% to $582.8 million in 2024, then decreased by 12.86% to $507.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $507.8 million in Q4 2025, $513.8 million in Q3 2025, and $519.0 million in Q2 2025.